secwatch.observer — SEC 8-K summary
======================================

Issuer:     Onconetix, Inc. (ONCO)
CIK:        0001782107
Form:       8-K
Filed at:   2024-02-12T23:59:59+00:00
Accession:  0001213900-24-012608
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconetix appoints Thomas Meier to board per Series B preferred holders' right
------------------------------------------------------------------------------

- Thomas Meier, PhD appointed as Class I director, term through 2025 annual meeting.
- Meier has 25+ years biotech experience; chairs Santhera Pharmaceuticals (SIX:SANN).
- Consulting agreement: CHF 400/hr as sellers' rep (Proteomedix deal) and CHF 350/hr as advisor.
- Appointment effective Feb 6, 2024; ratified by Audit Committee Feb 8, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782107/000121390024012608/0001213900-24-012608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782107/000121390024012608/ea193470-8k_onconetix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-012608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer